Literature DB >> 21444643

Pathophysiology of medication overuse headache: insights and hypotheses from preclinical studies.

Ian D Meng1, David Dodick, Michael H Ossipov, Frank Porreca.   

Abstract

INTRODUCTION: Medication overuse headache (MOH) is a clinical concern in the management of migraine headache. MOH arises from the frequent use of medications used for the treatment of a primary headache. Medications that can cause MOH include opioid analgesics as well as formulations designed for the treatment of migraine, such as triptans, ergot alkaloids, or drug combinations that include caffeine and barbiturates. LITERATURE REVIEW: Gathering evidence indicates that migraine patients are more susceptible to development of MOH, and that prolonged use of these medications increases the prognosis for development of chronic migraine, leading to the suggestion that similar underlying mechanisms may drive both migraine headache and MOH. In this review, we examine the link between several mechanisms that have been linked to migraine headache and a potential role in MOH. For example, cortical spreading depression (CSD), associated with migraine development, is increased in frequency with prolonged use of topiramate or paracetamol.
CONCLUSIONS: Increased CGRP levels in the blood have been linked to migraine and elevated CGRP can be casued by prolonged sumatriptan exposure. Possible mechanisms that may be common to both migraine and MOH include increased endogenous facilitation of pain and/or diminished diminished endogenous pain inhibition. Neuroanatomical pathways mediating these effects are examined.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21444643      PMCID: PMC5697138          DOI: 10.1177/0333102411402367

Source DB:  PubMed          Journal:  Cephalalgia        ISSN: 0333-1024            Impact factor:   6.292


  100 in total

1.  Chronic morphine exposure increases the proportion of on-cells in the rostral ventromedial medulla in rats.

Authors:  Ian D Meng; Ichiro Harasawa
Journal:  Life Sci       Date:  2007-02-24       Impact factor: 5.037

2.  Spreading depression: from serendipity to targeted therapy in migraine prophylaxis.

Authors:  C Ayata
Journal:  Cephalalgia       Date:  2009-10       Impact factor: 6.292

3.  Chronic daily headache in Taipei, Taiwan: prevalence, follow-up and outcome predictors.

Authors:  S R Lu; J L Fuh; W T Chen; K D Juang; S J Wang
Journal:  Cephalalgia       Date:  2001-12       Impact factor: 6.292

4.  Medications associated with probable medication overuse headache reported in a tertiary care headache center over a 15-year period.

Authors:  Chelsea A Meskunas; Stewart J Tepper; Alan M Rapoport; Fred D Sheftell; Marcelo E Bigal
Journal:  Headache       Date:  2006-05       Impact factor: 5.887

5.  Brain stem activation in spontaneous human migraine attacks.

Authors:  C Weiller; A May; V Limmroth; M Jüptner; H Kaube; R V Schayck; H H Coenen; H C Diener
Journal:  Nat Med       Date:  1995-07       Impact factor: 53.440

Review 6.  CGRP and its receptors provide new insights into migraine pathophysiology.

Authors:  Tony W Ho; Lars Edvinsson; Peter J Goadsby
Journal:  Nat Rev Neurol       Date:  2010-09-07       Impact factor: 42.937

7.  Effects of tonabersat on migraine with aura: a randomised, double-blind, placebo-controlled crossover study.

Authors:  Anne W Hauge; Mohammed S Asghar; Henrik W Schytz; Karl Christensen; Jes Olesen
Journal:  Lancet Neurol       Date:  2009-06-29       Impact factor: 44.182

8.  Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine.

Authors:  Jes Olesen; Hans-Christoph Diener; Ingo W Husstedt; Peter J Goadsby; David Hall; Ulrich Meier; Stephane Pollentier; Lynna M Lesko
Journal:  N Engl J Med       Date:  2004-03-11       Impact factor: 91.245

9.  Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial.

Authors:  Tony W Ho; Michel D Ferrari; David W Dodick; Vince Galet; James Kost; Xiaoyin Fan; Heather Leibensperger; Samar Froman; Christopher Assaid; Christopher Lines; Hille Koppen; Paul K Winner
Journal:  Lancet       Date:  2008-11-25       Impact factor: 79.321

10.  Calcitonin gene-related peptide (CGRP) levels during glyceryl trinitrate (GTN)-induced headache in healthy volunteers.

Authors:  C Kruuse; H K Iversen; I Jansen-Olesen; L Edvinsson; J Olesen
Journal:  Cephalalgia       Date:  2010-02-11       Impact factor: 6.292

View more
  14 in total

Review 1.  Dependent behavior in patients with medication-overuse headache.

Authors:  Jong-Ling Fuh; Shuu-Jiun Wang
Journal:  Curr Pain Headache Rep       Date:  2012-02

Review 2.  Medication-overuse headache: epidemiology, diagnosis and treatment.

Authors:  Espen Saxhaug Kristoffersen; Christofer Lundqvist
Journal:  Ther Adv Drug Saf       Date:  2014-04

3.  Increased susceptibility to cortical spreading depression in an animal model of medication-overuse headache.

Authors:  A Laine Green; Pengfei Gu; Milena De Felice; David Dodick; Michael H Ossipov; Frank Porreca
Journal:  Cephalalgia       Date:  2013-12-11       Impact factor: 6.292

Review 4.  Post-traumatic Headache: Pharmacologic Management and Targeting CGRP Signaling.

Authors:  Håkan Ashina; David W Dodick
Journal:  Curr Neurol Neurosci Rep       Date:  2022-02-09       Impact factor: 5.081

5.  Sumatriptan improves postoperative quality of recovery and reduces postcraniotomy headache after cranial nerve decompression.

Authors:  L Venkatraghavan; L Li; T Bailey; P H Manninen; M Tymianski
Journal:  Br J Anaesth       Date:  2016-07       Impact factor: 9.166

Review 6.  Medication-overuse headache: a review.

Authors:  Espen Saxhaug Kristoffersen; Christofer Lundqvist
Journal:  J Pain Res       Date:  2014-06-26       Impact factor: 3.133

Review 7.  CGRP and the Trigeminal System in Migraine.

Authors:  Smriti Iyengar; Kirk W Johnson; Michael H Ossipov; Sheena K Aurora
Journal:  Headache       Date:  2019-04-14       Impact factor: 5.887

8.  Discovery by a proteomic approach of possible early biomarkers of drug-induced nephrotoxicity in medication-overuse headache.

Authors:  Elisa Bellei; Emanuela Monari; Aurora Cuoghi; Stefania Bergamini; Simona Guerzoni; Michela Ciccarese; Tomris Ozben; Aldo Tomasi; Luigi Alberto Pini
Journal:  J Headache Pain       Date:  2013-01-30       Impact factor: 7.277

9.  Nabilone for the treatment of medication overuse headache: results of a preliminary double-blind, active-controlled, randomized trial.

Authors:  Luigi Alberto Pini; Simona Guerzoni; Maria Michela Cainazzo; Anna Ferrari; Paola Sarchielli; Ilaria Tiraferri; Michela Ciccarese; Maurizio Zappaterra
Journal:  J Headache Pain       Date:  2012-10-16       Impact factor: 7.277

Review 10.  The role of calcitonin gene-related peptide in peripheral and central pain mechanisms including migraine.

Authors:  Smriti Iyengar; Michael H Ossipov; Kirk W Johnson
Journal:  Pain       Date:  2017-04       Impact factor: 7.926

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.